adding current work

claude_rewrite
will king 1 year ago
parent 014ffa1a81
commit b83e15200e

@ -5,9 +5,9 @@ How do I begin work on stuff
- we can't trust what we are told - we can't trust what we are told
- terminations could be due to safety, strategic, or operational concerns. - terminations could be due to safety, strategic, or operational concerns.
- explaining confounding between - explaining confounding between
- population/market and enrollment.
-population/market and market conditions. -population/market and market conditions.
- market conditions and enrollment. - market conditions and enrollment.
- population/market and enrollment.
- describe other confounders - describe other confounders
- safety and effectiveness - safety and effectiveness
- duration <--> enrollment/termination - duration <--> enrollment/termination
@ -17,6 +17,7 @@ How do I begin work on stuff
- Introduce Do-Calculus - Introduce Do-Calculus
- DAG model - DAG model
- What do I need to control for, in some form or other? - What do I need to control for, in some form or other?
CURRENTLY HERE:
- Introduce Data - Introduce Data
- Clinical Trial Progression - Clinical Trial Progression
- AACT gives us information on - AACT gives us information on

@ -244,21 +244,35 @@ A quick summary of the nodes of the DAG and their impact:
$\rightarrow$ $\rightarrow$
\texttt{Enrollment Status}: \texttt{Enrollment Status}:
This confounds the estimation of the effect of This confounds the estimation of the effect of
\texttt{Enrollment} on \texttt{Will Terminate?}, and
so \texttt{Market Measures} is part of the adjustment set.
\item \item
\texttt{Market Measures} \texttt{Market Measures}
$\rightarrow$ $\rightarrow$
\texttt{Decision to proceed with Phase III}: \texttt{Decision to proceed with Phase III}:
The alternative treatments on the market will affect a sponsors' The alternative treatments on the market will affect a sponsors'
decision to move forward with a Phase III trial. decision to move forward with a Phase III trial.
This is controlled for by only working with trials that
successfully begin recruitment for a Phase III Trial.
\item \item
\texttt{Elapsed Duration} \texttt{Elapsed Duration}
$\rightarrow$ $\rightarrow$
\texttt{Will Terminate?}: \texttt{Will Terminate?}:
The amount of time past helps drive the decision to continue
or terminate.
\item \item
\texttt{Enrollment Status} \texttt{Enrollment Status}
$\leftrightarrow$ $\leftrightarrow$
\texttt{Elapsed Duration}: \texttt{Elapsed Duration}:
% This is jointly determined. and the weakest part of the causal identification without an accurate model of enrollment. % This is jointly determined. and the weakest part of the causal identification without an accurate model of enrollment.
This is one of the weakest parts of the causal inference.
Without a well defined model of enrollment, we can't separate
the interaction between the enrollment status and the elapsed
duration.
For example, if enrollment is running slower than expected,
the trial may be terminated due to concerns that it will not
achive the primary objectives or that costs will exceed
the budget allocated to the project.
\item \item
\texttt{Decision to Proceed with Phase III} \texttt{Decision to Proceed with Phase III}
$\rightarrow$ $\rightarrow$

Loading…
Cancel
Save